--Industry veteran CFO joins at critical juncture--

--ARU-2801 is a potentially curative gene therapy in development for individuals with hypophosphatasia (HPP)--

--Data demonstrates promise for lead program, ARU-1801, as potentially curative treatment for sickle cell disease--

--Data suggest individualized melphalan dosing prior to ARU-1801 infusion may improve patient outcomes--

--Data demonstrates treatment with ARU-1801 resulted in meaningful improvements in clinical outcomes for participants with severe sickle cell disease--

--Data from improved manufacturing process resulted in significantly improved ARU-1801 product profile--

--Ongoing manufacturing improvements shows enhanced efficacy of ARU-1801 for the treatment of sickle cell disease--

--Dr. Palaniappan joins Aruvant from Sarepta where he oversaw technical operations and was responsible for the development and registration of a portfolio of more than 30 compounds including gene therapies for rare diseases--

--Dr. McIntosh joins to lead clinical development at Aruvant, including the program for ARU-1801, a one-time potentially curative gene therapy for patients with sickle cell disease administered with reduced intensity conditioning--

ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and β-thalassemia

ARU-1801 is being developed as a potential one-time treatment for patients suffering from sickle cell disease and β-thalassemia

Chou joins Aruvant from Novartis, where he most recently led the global commercial launch of Kymriah®, the first CAR-T cell therapy, in North America, Europe and Asia

Two patients have been administered RVT-1801 in conjunction with reduced intensity conditioning regimens